Patients with early stage CLL: new risk stratification based on molecular profiling

[Guest guest]

BlankPatients with early stage chronic lymphocytic leukemia: new risk

stratification based on molecular profiling.

D Antic, B Mihaljevic, V Cokic, MD Fekete, TK Djurasevic, S Pavlovic, N Milic,

and I Elezovic

Leuk Lymphoma, July 1, 2011; 52(7): 1394-7.

Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia.

Abstract We investigated molecular and biological parameters reflecting the

biology of chronic lymphocytic leukemia (CLL) that may help us to predict the

time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL

(Binet stage A) were analyzed. We developed a new scoring system based on the

serum levels of ?(2)-microglobulin (?(2)M) and vascular endothelial growth

factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a

score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased

levels of ?(2)M, LPL, and VEGF) had a significantly shorter TTT of only 10.6

months (p < 0.0001).

PMID: 21699385